Taihua Plc Trading Update (2699U)
06 Aprile 2016 - 8:00AM
UK Regulatory
TIDMTAIH
RNS Number : 2699U
Taihua Plc
06 April 2016
Taihua plc
("Taihua" or the "Company")
Trading Update
Taihua, the China-based pharmaceutical company specialising in
the cultivation of Traditional Chinese Medicine ("TCM") raw
materials, manufacture of TCM and certain Active Pharmaceutical
Ingredients, would like to update its shareholders on its progress
in 2015 before the release of its financial results for the
financial year ended 31 December 2015.
Sales
Total Sales for 2015 were RMB 35.0m (2014: RMB 53.1m)
Forsythia
The combined harvest of the two plantations was 704 tonnes
(2014: 1,145 tonnes). The reduction was primarily due to adverse
weather conditions in the Winter and Spring periods. Given the
reduced harvest the Company is working with Research Institutes to
investigate ways that the harvest can be maximised in the future.
This includes measures such as more frost-resistant strains
In 2015 the average selling price was RMB38.93/kg (2014:
RMB37.77/kg) excluding sales tax. The Company did not see a further
significant increase in the selling price of Forsythia as the
adverse weather conditions were largely limited to the region that
Taihua obtains its harvest from. Other areas were, in the main,
unaffected by poor weather and, as such, their harvest was at a
more normal level
As a result the overall revenue derived from Forsythia in 2015
was RMB27.4m (2014: RMB 43.27m). The entire harvest has been
sold.
Bian Tong Pian
Bian Tong Pian sales in 2015 were 193,000 boxes (2014:191,600)
at an average selling price of RMB11.15 (2014: RMB13.30) per box.
This generated revenues of RMB2.152m (2014:RMB2.548m).
Other Traditional Chinese Medicines
Sales of other Traditional Chinese Medicines were RMB2.440m
(2014:RMB2.314m)
Active Pharmaceutical Ingredients (APIs)
Sales of Paclitaxel in 2015 were RMB2.411m (2014:RMB2.870m)
being 6,150g (2014:7,300g) at an average price of RMB392.03/g
(2014:RMB393.16/g).
Sales of Homoharringtonine in 2015 were RMB0.556m
(2014:RMB1.362m) being 400g (2014:960g) at an average price of
RMB1,388.9/g (2014:RMB1418.8/g).
Outlook
The Company spent much of 2015 concentrating on the
re-application for Chinese GMP certification. As previously
announced, this has been achieved. This, combined with the renewal
of the Company's Drug Production Permit means that there are no
regulatory barriers to the expansion of the Company's TCM
(including Bian Tong Pian) and Homoharringtonine sales.
The Company intends to spend much of 2016 in leveraging the
re-certification, paying particular attention to recovering market
share in Homoharringtonine and in expanding its distribution of
Bain Tong Pian. The sales of both of these products have been
severely constrained by the unstable GMP environment which has now
come to an end.
Enquiries:
Nicholas Lyth, Taihua plc 07769 906 686
Katy Mitchell, WH Ireland Limited +44 161 832 2174
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTLLFEESTIEIIR
(END) Dow Jones Newswires
April 06, 2016 02:00 ET (06:00 GMT)
Grafico Azioni Taihua (LSE:TAIH)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Taihua (LSE:TAIH)
Storico
Da Giu 2023 a Giu 2024